High-dimensional immune profiling of dimethyl fumarate and ocrelizumab in multiple sclerosis
Preprint
Abstract
Background: Dimethyl fumarate (DMF) and ocrelizumab are two effective immunomodulators for multiple sclerosis (MS) with distinct mechanisms of action. Identifying overlapping therapeutic effects between both agents may elucidate common pathways in preventing disease activity. Objectives: In this study we analyzed cytokine and immune-profiling data to evaluate the similarities and differences between the two disease-modifying therapies for MS. Methods : Plasma and PBMCs from MS patients were collected at baseline, 3 months and 6 months after treatment with DMF (n=16) and ocrelizumab (n=13). Immunophenotyping was performed with mass cytometry (CyTOF) and analyzed with gating based on cell surface markers. Cytokine analysis from plasma was performed with Olink assays and analyzed with linear mixed effects models. Results: DMF reduced both effector T and memory B cell populations while increasing CD56 bright natural killer (NK) cells. Ocrelizumab exerted its main immunomodulatory effect by reducing the frequency of all B cells and increasing frequency of NK cells. At 6 months, naive B-cells began to reconstitute; however, memory B cells remain depleted. DMF treatment was associated with a significant reduction of plasma cytokines involved in inflammatory pathways, such as IL-6, IL-12, and Dectin-1 signaling. In addition, DMF lowered plasma cytokines that are dysregulated in psoriasis and involved in allograft rejection pathways. Ocrelizumab treatment led to the upregulation of neurotropic proteins in the plasma of MS patients, including proteins involved in NAD+ biosynthesis and tryptophan catabolism. Conclusion: Our high-dimensional immunophenotyping results suggest that to exert their effects on MS patients, DMF and ocrelizumab both increase NK cells in addition to affecting different immune cell populations and cytokine pathways. Detecting similarities between the mechanisms of the two drugs may contribute to identifying more specific therapeutic targets.Keywords
This publication has 50 references indexed in Scilit:
- CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen speciesJournal of Neuroinflammation, 2012
- Unexpected Role for Granzyme K in CD56bright NK Cell-Mediated Immunoregulation of Multiple SclerosisThe Journal of Immunology, 2011
- Memory B cells from a subset of treatment‐naïve relapsing‐remitting multiple sclerosis patients elicit CD4+ T‐cell proliferation and IFN‐γ production in response to myelin basic protein and myelin oligodendrocyte glycoproteinEuropean Journal of Immunology, 2010
- Depletion of functionally active CD20+ T cells by rituximab treatmentArthritis & Rheumatism, 2009
- Sialoadhesin-Positive Macrophages Bind Regulatory T Cells, Negatively Controlling Their Expansion and Autoimmune Disease ProgressionThe Journal of Immunology, 2009
- Effect of hematopoietic growth factors on severity of experimental autoimmune encephalomyelitisBone Marrow Transplantation, 2006
- Collection, Processing, and Storage of Biological Samples in Epidemiologic Studies: Sex Hormones, Carotenoids, Inflammatory Markers, and Proteomics as ExamplesCancer Epidemiology, Biomarkers & Prevention, 2006
- Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan MetaboliteScience, 2005
- Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissueJournal of Neuroimmunology, 2000
- Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.Journal of Experimental Medicine, 1996